Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study

Journal of Viral Hepatitis

Volumn 22, Issue 9, 2015, Pages 708-717

  Hajarizadeh, B ^a   Grady, B ^b   Page, K ^c   Kim, A Y ^d   McGovern, B H ^e,f   Cox, A L ^g   Rice, T M ^c   Sacks Davis, R ^h,i   Bruneau, J ^j   Morris, M ^c   Amin, J ^a   Schinkel, J ^k   Applegate, T ^a   Maher, L ^a   Hellard, M ^h,i   Lloyd, A R ^l   Prins, M ^b,k   Geskus, R B ^b,k   Dore, G J ^a   Grebely, J ^a   InC, ^c   more..

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f ABBVIE INC   (United States)

^g DEPARTMENT OF PATHOLOGY   (United States)

^h BURNET INSTITUTE   (Australia)

ⁱ MONASH UNIVERSITY   (Australia)

^j CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^k ACADEMIC MEDICAL CENTER   (Netherlands)

^l UNIVERSITY OF NEW SOUTH WALES   (Australia)

more..

Author keywords

cohort study; HCV genotype; HIV; IFNL4 genotype; IL28B genotype; sex; viral load

Indexed keywords

VIRUS RNA; IFNL4 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; EARLY DIAGNOSIS; FEMALE; GEOGRAPHIC DISTRIBUTION; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IFNL4 GENE; IMMUNOPATHOGENESIS; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NONHUMAN; PRIORITY JOURNAL; RNA ANALYSIS; SEX DIFFERENCE; VIRUS GENE; VIRUS LOAD; VIRUS PATHOGENESIS; VIRUS VIRULENCE; BLOOD; CHRONIC HEPATITIS C; CLASSIFICATION; COMPLICATION; GENETICS; GENOTYPE; HEPACIVIRUS; INTERNATIONAL COOPERATION; ISOLATION AND PURIFICATION; MIDDLE AGED; PROSPECTIVE STUDY; VIROLOGY; YOUNG ADULT;

ADULT; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERLEUKINS; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RNA, VIRAL; SEX FACTORS; VIRAL LOAD; YOUNG ADULT;

EID: 84936846157     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12384     Document Type: Article

References (52)

1. Hajarizadeh B, Grebely J, Dore GJ,. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013; 10 (9): 553-562.
2. Grebely J, Dore GJ,. What is killing people with hepatitis C virus infection? Semin Liver Dis 2011; 31 (04): 331-339.
3. Zeuzem S, Rodríguez-Torres M, Rajender Reddy K, et al,. Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin. J Viral Hepatitis 2012; 19 (11): 766-774.
4. Manns MP, McHutchison JG, Gordon SC, et al,. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358 (9286): 958-965.
5. McHutchison JG, Lawitz EJ, Shiffman ML, et al,. Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection. N Engl J Med 2009; 361 (6): 580-593.
6. Poordad F, McCone J, Bacon BR, et al,. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364 (13): 1195-1206.
7. Poordad F, Bronowicki JP, Gordon SC, et al,. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012; 143 (3): 608-618.e5.
8. McHutchison JG, Manns MP, Muir AJ, et al,. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362 (14): 1292-1303.
9. Lawitz E, Poordad FF, Pang PS, et al,. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014; 383 (9916): 515-523.
10. Jacobson IM, Gordon SC, Kowdley KV, et al,. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368 (20): 1867-1877.
11. Uccellini L, Tseng FC, Monaco A, et al,. HCV RNA levels in a multiethnic cohort of injection drug users: human genetic, viral and demographic associations. Hepatology 2012; 56 (1): 86-94.
12. McCarthy JJ, Li JH, Thompson A, et al,. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138 (7): 2307-2314.
13. Ge D, Fellay J, Thompson AJ, et al,. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461 (7262): 399-401.
14. Labarga P, Soriano V, Caruz A, et al,. Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients. AIDS 2011; 25 (6): 761-766.
15. Rong X, Lu L, Wang J, et al,. Correlation of viral loads with HCV genotypes: higher levels of virus were revealed among blood donors infected with 6a strains. PLoS ONE 2012; 7 (12): e52467.
16. McMahon BJ, Hennessy TW, Christensen C, et al,. Epidemiology and risk factors for hepatitis C in Alaska Natives. Hepatology 2004; 39 (2): 325-332.
17. Fishbein DA, Lo Y, Netski D, Thomas DL, Klein RS,. Predictors of hepatitis C virus RNA levels in a prospective cohort study of drug users. J Acquir Immune Defic Syndr 2006; 41 (4): 471-476.
18. Thomas DL, Astemborski J, Vlahov D, et al,. Determinants of the quantity of hepatitis C virus RNA. J Infect Dis 2000; 181 (3): 844-851.
19. Rauch A, Gaudieri S, Evison J, et al,. Low current and nadir CD4+ T-cell counts are associated with higher hepatitis C virus RNA levels in the Swiss HIV cohort study. Antivir Ther 2008; 13 (3): 455-460.
20. Grint D, Peters L, Reekie J, et al,. Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy. HIV Med 2013; 14 (6): 370-378.
21. Yoo TW, Donfield S, Lail A, et al,. Effect of hepatitis C virus (HCV) genotype on HCV and HIV-1 disease. J Infect Dis 2005; 191 (1): 4-10.
22. Grady BPX, Prins M, Rebers S, Molenkamp R, Geskus RB, Schinkel J,. BMI, male sex and IL28B genotype associated with persistently high hepatitis C virus RNA levels among chronically infected drug users up to 23 years following seroconversion. J Viral Hepatitis 2014 Sep 1; doi: 10.1111/jvh.12303. [Epub ahead of print].
23. Grebely J, Morris MD, Rice TM, et al,. Cohort profile: the international collaboration of incident HIV and hepatitis C in injecting cohorts (InC3) study. Int J Epidemiol 2012; 42 (6): 1649-1659.
24. Hajarizadeh B, Grebely J, Applegate T, et al,. Dynamics of HCV RNA levels during acute hepatitis C virus infection. J Med Virol 2014; 86 (10): 1722-1729.
25. Hajarizadeh B, Page K, Kim AY, et al,. Early HCV RNA dynamics and factors associated with high early HCV RNA level during acute HCV infection. J Hepatol 2013; 1: S470-S471 [Abstract].
26. Page-Shafer K, Pappalardo BL, Tobler LH, et al,. Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates. J Clin Microbiol 2008; 46 (2): 499-506.
27. Cox AL, Netski DM, Mosbruger T, et al,. Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis 2005; 40 (7): 951-958.
28. Hofer H, Watkins-Riedel T, Janata O, et al,. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology 2003; 37 (1): 60-64.
29. Busch MP, Page Shafer KA,. Acute-phase hepatitis C virus infection: implications for research, diagnosis, and treatment. Clin Infect Dis 2005; 40 (7): 959-961.
30. Badr G, Bédard N, Abdel-Hakeem MS, et al,. Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells. J Virol 2008; 82 (20): 10017-10031.
31. van de Laar TJW, Molenkamp R, van den Berg C, et al,. Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam. J Hepatol 2009; 51 (4): 667-674.
32. Grebely J, Petoumenos K, Hellard M, et al,. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology (Baltimore, MD) 2010; 52 (4): 1216-1224.
33. Thomas DL, Thio CL, Martin MP, et al,. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461 (7265): 798-801.
34. van den Berg CHBS, Grady BPX, Schinkel J, et al,. Female sex and IL28b, a synergism for spontaneous viral clearance in hepatitis c virus (HCV) seroconverters from a community-based cohort. PLoS ONE 2011; 6 (11): e27555.
35. Grebely J, Page K, Sacks-Davis R, et al,. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology 2014; 59 (1): 109-120.
36. Prokunina-Olsson L, Muchmore B, Tang W, et al,. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013; 45 (2): 164-171.
37. Liu L, Fisher BE, Thomas DL, Cox AL, Ray SC,. Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. Hepatology 2012; 55 (6): 1684-1691.
38. Hajarizadeh B, Grady B, Page K, et al,. Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: the InC3 Study. J Clin Virol 2014; 61 (3): 430-434.
39. Tillmann HL, Thompson AJ, Patel K, et al,. A polymorphism near IL28B Is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010; 139 (5): 1586-1592.
40. Honda M, Sakai A, Yamashita T, et al,. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139 (2): 499-509.
41. Urban TJ, Thompson AJ, Bradrick SS, et al,. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010; 52 (6): 1888-1896.
42. Hamming OJ, Terczyńska-Dyla E, Vieyres G, et al,. Interferon lambda 4 signals via the IFNλ receptor to regulate antiviral activity against HCV and coronaviruses. EMBO J 2013; 32 (23): 3055-3065.
43. Page K, Hahn JA, Evans J, et al,. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis 2009; 200 (8): 1216-1226.
44. Micallef JM, Kaldor JM, Dore GJ,. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepatitis 2006; 13 (1): 34-41.
45. Klein SL, Jedlicka A, Pekosz A,. The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis 2010; 10 (5): 338-349.
46. Bouman A, Heineman MJ, Faas MM,. Sex hormones and the immune response in humans. Hum Reprod Update 2005; 11 (4): 411-423.
47. Meier A, Chang JJ, Chan ES, et al,. Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat Med 2009; 15 (8): 955-959.
48. Floreani A, Cazzagon N, Boemo DG, et al,. Female patients in fertile age with chronic hepatitis C, easy genotype, and persistently normal transaminases have a 100% chance to reach a sustained virological response. Eur J Gastro Hepatol 2011; 23 (11): 997-1003.
49. Villa E, Karampatou A, Camm C, et al,. Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C. Gastroenterology 2011; 140 (3): 818-829.
50. Hillung J, Ruiz-López E, Bellón-Echeverría I, Clemente-Casares P, Mas A,. Characterization of the interaction between hepatitis C virus NS5B and the human oestrogen receptor alpha. J Gen Virol 2012; 93 (Pt 4): 780-785.
51. Lin W, Weinberg EM, Tai AW, et al,. HIV increases HCV replication in a TGF-beta1-dependent manner. Gastroenterology 2008; 134 (3): 803-811.
52. Zhang X, Daucher M, Baeza J, Kim CW, Russell R, Kottilil S,. Human immunodeficiency virus enhances hepatitis C virus replication by differential regulation of IFN and TGF family genes. J Med Virol 2012; 84 (9): 1344-1352.